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The rates of breast cancer mortality remain high in Brazil. Docetaxel is a semi-synthetic taxane used 
to treat various tumors, particularly tumors of the breast, lung and prostate. In this study ADR that 
occurred in 45 docetaxel users with breast cancer were surveyed. They were identified by type, causality 
(Naranjo algorithm and World Health Organization categories) and, if considered probable or defined, 
rated for severity according to SOBRAFO proposal (2007). A total of 325 ADR were observed: 165 in 
the first, 137 in the second and 23 in the third cycle. Fifty seven ADR were immediate and the others, 
late. Fatigue and exhaustion for more than five days, classified as Grade 3 by SOBRAFO (2007), were 
reported as the primary late RAM. There was no significant difference in the occurrence of immediate 
and late ADR between cycles (p=1 and p=0.3577, respectively). The presence of a pharmacist gave the 
patients a better understanding of the occurrence of RAM, especially those that occur outside the hospital, 
between chemotherapy cycles and are often not reported to the healthcare team, creating institutional 
demands and reaching the goal to track, observe and correlate the RAM for each user.
Uniterms: Docetaxel/adverse reactions. Drugs/adverse reactions. Breast Cancer/tretament/reactions.
As taxas de mortalidade por câncer de mama no Brasil permanecem altas. O docetaxel é um taxano 
semi-sintético usado para tratar vários tumores, particularmente tumores da mama, pulmão e próstata. 
Neste estudo, as Reações Adversas (RAM) ocorridas em 45 pacientes com câncer de mama foram 
monitoradas. Elas foram classificadas pelo tipo e causalidade (Algoritmo de Naranjo e categorias 
propostas pela Organização Mundial da Saúde) e, se consideradas prováveis ou definidas, foram 
classificadas também pela severidade, de acordo com a proposta da SOBRAFO (2007). Um total de 
325 RAM foram observadas: 165 no primeiro, 137 no segundo e 23 no terceiro ciclo. Cinquenta e sete 
RAM foram imediatas e as demais tardias. Fadiga e exaustão por mais de 5 dias, classificadas como grau 
3 pela SOBRAFO (2007), foram as principais RAM encontradas. Não houve diferença significativa na 
ocorrência de RAM imediatas ou tardias entre os ciclos (p=1 e p=0,3577, respectivamente). A presença 
de um farmacêutico proporcionou aos pacientes um melhor entendimento sobre a ocorrência de RAM, 
especialmente sobre aquelas que ocorrem fora do ambiente hospitalar, entre os ciclos da terapia, não 
sendo usualmente relatadas aos profissionais de saúde. Isto gerou uma demanda na instituição e permitiu 
alcançar a meta de acompanhar, observar e correlacionar as RAM de cada paciente. 
Unitermos: Docetaxel/reações adversas. Medicamentos/reações adversas. Câncer de mama/tratamento/
reações.
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INTRODUCTION
Although breast cancer has a relatively good 
prognosis, the rates of breast cancer mortality remain high 
in Brazil, most likely because the disease is still diagnosed 
in its advanced stages. According to the Ministry of 
Health, in 2012, 52,680 new cases of breast cancer were 
predicted, with an estimated risk of 52 cases per 100,000 
women (INCA, 2011).
Docetaxel is a semi-synthetic taxane that is obtained 
from a precursor derived from the European tree Taxus 
baccata (Sweetman, 2008). It has been used to treat 
various tumors, particularly tumors of the breast (Bear 
et al., 2003; Jones et al., 2006), lung (Noble et al., 2006) 
and prostate (Kelly et al., 2009). Its use can bring benefits 
such as increasing life expectancy and decreasing tumors, 
tumor progression and risk of relapse (Ghersi et al., 
2015). It is used as a first-line therapeutic treatment in 
combination with trastuzumab, a monoclonal antibody 
specific for HER2 receptor in metastatic breast cancers 
that express the HER2 receptor. As an adjuvant treatment 
of operable breast cancers that are lymph node positive, 
docetaxel can be administered with doxorubicin and 
cyclophosphamide (Sweetman, 2008). It can also be used 
alone, intravenously, as a neoadjuvant or as a palliative 
as a first, second or third choice, or in combination with 
cyclophosphamide every three weeks in adjuvant and 
neoadjuvant treatment (Brasil, 2006).
Adverse reactions to docetaxel have been reported 
for the gastrointestinal tract (ischemic colitis), heart 
(increased risk of heart failure), musculoskeletal system 
(arthralgia and myalgia), eyes (exacerbated tearing), skin 
and nails (foot-and-hand syndrome) and hypersensitivity 
reactions and tumor lysis syndrome (Sweetman, 2008). 
Cutaneous effects such as erythema (Tallon, Lamb, 2007) 
and onycholysis (Roh et al., 2007) are responsible for 
the significant reduction in the quality of life of users. 
Undesirable hematological effects have been reported 
worldwide (Yip, Chow, 2006). The most important of 
these is febrile neutropenia, which is a dose-limiting factor 
because of its influence on the quality of life of users.
The Brazilian Society of Oncology Pharmacists 
(Sobrafo) has classified Adverse Drug Reactions (ADR) 
based on event severity. This classification system consists 
of five levels, where the lowest level (level 0) is defined 
as any adverse event or events within normal limits and 
the highest level (level 5) is death (Sobrafo, 2007). Table I 
shows examples of adverse reactions to docetaxel and their 
different degrees of severity as reported in the literature.
In this study, the adverse drug reactions observed 
in docetaxel users were surveyed, through an embryonic 
process of pharmaceutical care in a chemotherapy service. 
They were identified by type (infusion, immediate or late), 
categorized according to the Naranjo algorithm and World 
Health Organization categories and, for those considered 
probable or defined, rated for severity using the Sobrafo 
proposal (2007).
METHODS
The study was conducted in a small federal hospital 
that specializes in breast cancer care in Rio de Janeiro, 
Brazil. This unit is ambulatory and has 56 inpatient beds, a 
surgical center, and Radiotherapy and Chemotherapy units, 
but it lacks an Intensive Care Unit. The unit integrates the 
Sentinel Hospitals Program Hospital, a pharmacovigilance 
project of the Brazil Ministry of Health.
Pharmacovigilance is achieved through volunteer 
event reports that are sent to the Pharmacovigilance 
Department, without an active search for undesirable 
effects. Two recruitment processes were conducted. The 
first consisted of the first 20 patients selected for docetaxel 
therapy at the Oncology Clinic in December 2008, and 
the second consisted of the first 25 patients enrolled 
from August 2010 at the same clinic. The beginning of 
docetaxel therapy at this hospital occurs only after a health 
care team meeting. These meetings are held weekly to 
reach a consensus on the treatment being offered. The use 
of docetaxel is exclusive for patients who are elected at 
this meeting.
In the first group, patients were recruited from 
December 6 to 15, 2008, and follow-up occurred during 
the three weeks after each administration of docetaxel, 
with the last contact made on March 26, 2009. With the 
second group, the same strategy was applied: recruitment 
was held from August 18, 2009, to January 16, 2010. 
For this group, the last contact occurred on January 10, 
2011.
The inclusion criteria were as follows: users aged 
18 or older who used docetaxel in adjuvant protocols, 
neoadjuvant or palliative treatment during the two months 
from the date of this project approval and agreement to 
participate by signing the consent form. The exclusion 
criteria were the presence of communication difficulty or 
a lack of oral language comprehension by the user.
The sample size was established considering that 
the maximum number of simultaneous users of the drug 
in this hospital was 185 and that the lowest incidence of 
RAM to docetaxel reported in the literature was 10%. In 
addition, we selected an absolute precision of 10% and a 
confidence level of 95%. The minimum sample size of 10 
patients was calculated by the software EPi INFO 7.1.4.0.
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After selection at the Clinical Meeting, patients 
scheduled the first docetaxel administration date at 
the chemotherapy center. According to this schedule, 
the pharmacist approached patients at this location, 
presenting the project and requesting their signature on 
the consent form. Only after this signature was obtained 
was Questionnaire 1 administered. This questionnaire 
concerned the patient’s demographic data.
After drug administration, the patient returned to 
the Chemotherapy Center office to schedule their second 
medication cycle. The pharmacist was then informed of 
this date. On the appointed day, the pharmacist was once 
again with the patient during docetaxel administration 
and administered Questionnaire 2. This questionnaire, 
originally developed and validated to use in pregnant 
women by Canova (2005), was selected due to its 
simplicity and ease of understanding by the patient. It was 
previously validated to use with our patients, during a pilot 
test. The interview was held with the user and/or caregiver. 
This questionnaire was designed to capture information 
about the occurrence of late reactions (i.e., those that occur 
from three days after administration of the drug) during 
the period between treatments.
At least three weeks after the last administration, 
TABLE I - Example of RAM related to docetaxel, according to type and severity
RAM
Classification
Font
Temporal Severity
Fatigue Late 3 to 4 Engels, Verweij (2005)
Hives Infusional/ Immediate 3 Limswuan, Demoly (2010)
Angioedema Immediate 3
Limswuan,Demoly (2010); Raschi et al. 
(2010); Rodriguez-Frias, Lee (2007); Engels, 
Verweij (2005)
Anaphylaxis Infusional /Immediate 3 to 4 Limswuan & Demoly (2010); Raschi et al. (2010)
Anaphylactic shock Infusional/ Immediate 4 to 5 Limswuan, Demoly (2010)
Vasodilation Late 3 Raschi et al.(2010)
Hypotension Infusional/ Immediate 3 Raschi et al. (2010)
Syncope Late 4 to 5 Raschi et al. (2010), Monsuez et al. (2010)
Phlebitis Late 3 Raschi et al. (2010)
Liver damage Late 3 to 4 Rodriguez-Frias, Lee (2007)
Peripheral Neuropathy Late 3 Rodriguez-Frias, Lee (2007), Engels., Verweij 
(2005); Argyriou et al. (2008)
Neutropenia Late 4 Rodriguez-Frias, Lee (2007); Engels, Verweij (2005)
Bradycardia Immediate/ Late 3 to 4 Monsuez et al. (2010)
Arrhythmia Late 3 to 5 Monsuez et al. (2010)
Myocardial Ischemia Late 3 to 5 Monsuez et al. (2010)
Pericardial Effusion Late 4 to 5 Monsuez et al. (2010)
Anemia Late 3 to 5 Engels,Verweij (2005); Boneterre (1999)
Thrombocytopenia Late 3 to 4 Engels, Verweij (2005); Boneterre (1999)
Febrile Neutropenia Late 4 to 5 Engels, Verweij (2005); Boneterre (1999)
Náusea Immediate/ Late 3 to 4 Engels, Verweij (2005)
Vomit Immediate/ Late 3 to 4 Engels, Verweij (2005)
Diarrhea Immediate/ Late 3 to 4 Engels, Verweij (2005)
Stomatitis Late 3 to 4 Engels, Verweij (2005)
Erythrodysesthaesia palmar –
plantar Late 3 to 4 Kara, Sahin, Erkisi (2006)
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the second questionnaire was administered again by 
telephone, so that data were collected for the period after 
the last drug administration. To prevent the interviewer 
from introducing bias, if the patient did not understand 
the question, it was read again. If necessary, a synonym 
to medical expressions was used like, for example, high 
blood pressure instead of hypertension. All patients 
underwent 3 cycles of docetaxel administration, with an 
interval of 23 days between them, unless the patient were 
to death.
In addition, we directly observed patients receiving 
docetaxel in the hospital to detect infusion reactions, which 
are those that occur at the time of drug administration. 
Patient records were also analyzed to search for additional 
information. 
The causality of the suspect RAM was determined 
using the Naranjo Algorithm (Louro, Romano-Lieber, 
Ribeiro, 2007) and the cathegories proposed by the World 
Health Organization (WHO) (OPAS, 2011). To identify 
data in the literature concerning the event under suspicion, 
the following bibliographic databases were used: the 
product label, a reference book (Sweetman, 2008) and 
related articles (Roh et al., 2007; Baker et al., 2008). The 
temporal analysis of the adverse reactions was determined 
from direct observations of the drug administration, 
interviews and medical records. The appearance of the 
same RAM in two cycles of chemotherapy was considered 
recurrence of symptoms after re-exposure to the drug. It 
was not possible to measure the serum levels of the drug. 
However, the prescribed doses were checked against the 
literature. Alternative explanations of the symptoms were 
developed based on the literature and on discussions with 
the clinical staff accompanying the patient. Changes in 
dose (increase or decrease) were considered only when 
properly registered in the medical records. The use of 
drugs of the same family or with similar structure was 
considered for the analysis of item 9 of the Naranjo 
algorithm. 
This work was recorded on July 22, 2008, under N° 
075/08, and June 25, 2010, under No. 073/10. The study 
was approved by INCA´s Ethics Committee on October 
1, 2008, and August 13, 2010, and was in accordance with 
Resolution 196/96 of the National Council of Ethics in 
Human Research.
The data were stored and processed using Microsoft 
Excel®. We used descriptive statistics such as measures of 
frequency distribution, mean and standard deviation. To 
assess the statistical significance between differences in 
the occurrence of RAM in 3 cycles of chemotherapy with 
docetaxel, we used a 2 x 2 contingency table and Fisher´s 
exact test.
RESULTS AND DISCUSSION
Forty-five patients were followed. The sample 
contained only women, predominantly in the adjuvant 
treatment of breast cancer (51%), between 40 and 65 years 
old (82%), living in the metropolitan area of Rio de Janeiro 
State (82%), with 40% living in the capital itself. Most of 
the volunteers did not continue working during treatment 
(73%) and had less than 9 years of formal education 
(37%). The majority had at least one comorbidity (60 %), 
primarily hypertension, with a prevalence of 81.5%. 
In this study, difficulty of access or symptom 
improvement were reported as reasons for non-admittance 
to the Hospital during an adverse event, regardless of the 
severity of RAM in all cases. This result confirms the 
observations of DI Girólamo (2000), who found that the 
distance between the Hospital and the residence of the 
volunteers was a factor for non-adherence to treatment. 
This observation reinforces the need for the pharmacist 
to use a closer approach to effectively observe any ADRs 
that occur between cycles of docetaxel administration. 
Four volunteers did not complete the study. The 
causes were different in each case: death, change of 
antineoplastic treatment, protocol dropout and not 
understanding the study. Of those, three received two 
cycles of treatment, and one received only one dose. None 
of them reported RAM occurrence. The death was caused 
by the evolution of the disease, primarily lung and bone 
metastases. The antineoplastic protocol exchange took 
the appearance of brain metastases during treatment with 
docetaxel. In both cases, the volunteers were in palliative 
treatment. The case of non-adherence was due to social 
aspects: the volunteer had no means of transport and did 
not respond to queries because of her inability to pay 
transportation fees. 
According to the analysis of causality made by the 
Naranjo Algorithm (Louro, Romano-Lieber, Ribeiro, 
2007), all of the RAM were Probable. Applying the 
WHO categorization, 57,8% of the RAM were considered 
Defined, 42,1% were considered Probable and only 
one RAM was considered Possible. They were all were 
classified as late or immediate RAM. Immediate RAM 
begins three days after drug administration. Late RAM 
begins after the fourth day (OPAS, 2005). RAM severity 
was defined in accordance with the proposal of the 
Brazilian Society of Oncology Pharmacists (Sobrafo, 
2007). Table II indicates the prevalence of each RAM and 
the severity rating. The occurrence of neutropenia and 
fatigue is worth noting.
It is important to note the higher incidence of 
immediate adverse reactions in the first cycle of treatment 
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TABLE II - Immediate and late RAM to docetaxel in different treatment cycles distributed according to the frequency of individuals 
(N) and degree of severity, N= 325, Rio de Janeiro, 2010
RAM
1st Cycle 2nd Cycle 3rd Cycle
Immediate Late Immediate Late Immediate Late
N Degree* N Degree* N Degree* N Degree* N Degree* N Degree*
Alopecia - - - - - - - - - - 1 1
Changes in the nails - - - - - - - - 1 2 2 2
Anxiety - - 1 2 - - - - - - - -
Constipation 4 2 2 2 2 2 3 2 - - 1 2
Diarrhea 2 2 11 2 - - 10 2 1 2 9 2
Dyspnea 1 2 1 2 - - 1 2 - - 4 2
Headache - - 2 2 - - 3 2 - - 2 2
Backache - - 2 2 - - 2 2 - - - -
Leg pain - - - - 1 2 - - - - - -
Pain in the abdomen 1 2 3 2 1 2 3 2 1 2 4 2
Pain in the body 3 2 6 2 - - 5 2 - - 8 2
Pain in the tumor - - 1 2 - - - - - - 1 2
Pain in the limbs - - 6 2 - - 14 2 - - 8 2
Pain in the bones 1 2 3 2 1 2 3 2 1 2 4 2
Edema - - 2 2 - - 2 2 - - 2 2
Fatigue 4 3 20 3 4 3 18 3 1 3 15 33 4 4 4 4 4
Lack of appetite - - 5 1 - - - - - - 4 2
Lack of taste 1 2 7 2 - - 9 2 2 2 10 2
Insomnia - - 2 1 - - - - - - 2 2
Mucosal irritation 1 2 6 2 1 2 6 2 - - 7 2
Skin irritation - - 10 2 2 2 - - - - 1 2
Eye irritation - - 2 1 - - 1 2 - - 1 1
Nausea 4 2 12 2 4 2 11 2 - - 8 2
 Febrile Neutropenia - - 6 4 - - 2 4 - - 2 4
Hot flushes 1 1 - - - - - - - - 2 1
Paresthesia 1 2 2 2 - - 2 2 1 2 5 2
Itch - - 9 2 - - 3 2 - - 5 2
Gastric Reflux - - - - - - - - - - 1 2
Flushing 2 1   1 2 - - - - - -
Drooling - - - - - - 1 2 - - - -
Syndrome foot-and-hand 1 2 - - - - - - - - 2 2
Somnolence - - 2 1 - - 1 2 - - - -
Sweating - - 1 1 - - - - - - - -
Tachycardia - - 2 2 - - 3 2 - - 2 2
Dry cough - - 1 1 - - 1 2 - - 1 2
Tremor - - - - - - - - - - 1 1
Vertigo - - 3 2 2 2 2 2 - - 1 2
Blurred vision - - 1 2 2 2 - - - - - -
Vomit - - 3 2   4 2 - - 3 2
Xerostomia - - 1 3 1 3 1 3 - - - -
Total RAM 27 - 138 - 22 - 115 - 8 - 15 -
*Severity was established in accordance with Sobrafo (2007)
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compared with the second and third cycles, due to the 
initial drug exposure. As treatment continues, it is possible 
that the drug tolerance of the patient increases. It is 
noteworthy that the difference in the number of patients 
who showed immediate RAM among the three cycles was 
not statistically significant (p=0, 3577). There were more 
late reactions of more variety compared to the immediate 
reactions. For late reactions, there was no significant 
difference between cycles (p=1). Note that symptoms 
such as nausea, pain, fatigue, lack of taste, irritation (in 
skin or mucous membranes) and neutropenia occurred 
in all cycles in more than one patient. It is important to 
emphasize that there is a considerable reduction in the 
quality of life of patients with these symptoms, which is 
predictable and can be handled (Passareli, Jacob Filho, 
2007).
Another feature to note is the recurrence of adverse 
reactions among users (Table III). Twenty-one ADR were 
reported in two cycles, and 11 RAM were reported in the 
three cycles. The symptoms discussed in the previous 
paragraph were cited as recurring in two and three cycles, 
thus reinforcing their importance.
Fatigue and exhaustion for more than five days, 
classified as Grade 3 by Sobrafo (2007), were reported as 
the primary late RAM for most volunteers. Both fatigue 
and prostration were classified as Probable. These two 
symptoms were described previously by Machado and 
Sawada (2008) as symptoms with increasing rates in the 
adjuvant treatment of breast cancer and bowel after three 
months of treatment. This adverse reaction, although 
treatable, is often overlooked in cancer treatment and can 
sometimes be confused with the evolution of the illness 
(Mota, Pimenta, 2002; Menezes, Camargo, 2006). We 
must be alert to the possibility of one symptom worsening 
another, as described by Lamino, Mota, Pimenta (2011). 
For example, fatigue can exacerbate the symptoms of 
pain, supporting the presence of a cluster of symptoms in 
breast cancer. 
Another severe late RAM was febrile neutropenia, 
which was recurrent with thalassemia in one patient and 
non-recurring in eight other patients. This condition led 
to the hospitalization of the patients and was classified as 
grade 4. In such cases, a causal relation is likely. Febrile 
neutropenia is well known among the predictable RAM 
in breast cancer, and its management is widely reported 
(Gozzo et al., 2011). 
Some RAM to docetaxel, such as facial flushing 
and hypertensive crisis upon infusion, may be related 
to comorbidities. In this study, all volunteers who had 
infusion reactions were hypertensive, and one patient who 
had recurrent febrile neutropenia was thalassemic. The 
literature (Brasil, 2006) suggests that infusion RAM are 
more common among patients in neoadjuvant treatments. 
However, our results show more adverse reactions among 
patients taking docetaxel as an adjuvant (Figure 1). It 
is noteworthy that 100% of the participants had late 
RAM, regardless of protocol type in at least one cycle of 
treatment, as highlighted in Figure 1. Hypersensitivity 
was reported by 8% of volunteers. It is noteworthy that 
no questions about the product quality were reported 
during the study period and that hypersensitivity reactions 
occurred with different batches of the product.
The presence of a pharmacist gave the patients a 
better understanding of the occurrence of RAM related 
to the use of docetaxel, especially those RAM that occur 
outside the hospital between chemotherapy cycles. These 
reactions are often not reported to the healthcare team. 
The contribution of the pharmacist at the Chemotherapy 
Center was exemplary and reflected the members of the 
TABLE III - RAM to Docetaxel recurrence, N=45 patients, Rio 
de Janeiro, 2010
RAM
Recurrence
2 times 3 times
Constipation 4 0
Diarrhea 6 3
Headache 2 0
Backache 1 0
Pain in the limbs 7 2
Pain in the abdomen 2 1
Pain in the body 3 1
Pain in the bones 0 2
Edema 1 0
Fatigue 6 13
Lack of appetite 1 0
Lack of taste 4 3
Insomnia 1 0
Mucosal irritation 4 2
Skin irritation 3 0
Nausea 8 4
Febrile Neutropenia 1 0
Paresthesia 1 0
Itch 1 1
Tachycardia 0 1
Vertigo 1 0
Blurred vision 1 0
Vomit 1 0
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multidisciplinary team, creating institutional demands and 
reaching the goal to track, observe and correlate the RAM 
for each user. It is known that studies of this type reinforce 
the importance of pharmacovigilance and sensitize the 
entire multidisciplinary team. This sensitization may play 
a role in spontaneous ADR (Ribeiro-Vaz et al., 2011). 
The results, particularly the approach of the pharmacist 
to users of docetaxel, suggest that the implementation of 
an active pursuit of RAM in the intercycle period can be 
an important contribution of the Pharmacy Service in risk 
management, especially if this strategy can be expanded to 
other chemotherapy treatments offered by the institution.
Furthermore, as many late RAM ranged from 
moderate to severe, it is reasonable to suppose that they 
may therefore contribute to the impairment of treatment 
adherence or to a potential reduction in the patients’ quality 
of life. Besides, these events, in more severe cases, may 
also increase the patients’ risk of death. 
The limited number of patients, the limited follow 
up period, the self report of the RAM and, consequently, 
the possibility of vies of memory, constitute the main 
limitations of this study. These limitations require caution 
in generalizing the results. 
CONCLUSION
The objective of this work was an active search for 
adverse reactions to docetaxel among patients treated in a 
specialized breast cancer hospital in Rio de Janeiro. The 
results emphasize the necessity of monitoring adverse 
drug reactions during the inter cycle periods. The proposed 
methodology was adequate to the job, not only allowing 
the identification of the reactions of interest but also 
bringing the pharmacist closer to both the patients and 
the healthcare team. 
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